Company intelligence / Profile preview

FenDi Pharma

Ownership: Private
Development stage: Other

Overview

FenDi Pharma is an early-stage biotechnology company focused on developing innovative treatments for pain management and opioid use disorder. The company's research centers on the development of novel small molecule modulators of the opioid receptor system, aiming to provide effective analgesia with a significantly reduced risk of addiction and respiratory depression compared to traditional opioids. By leveraging advanced medicinal chemistry and pharmacological insights, FenDi Pharma seeks to address the critical public health challenge of the opioid crisis through safer therapeutic alternatives.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on FenDi Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FenDi Pharma.

Explore the full profile